Companies /Healthcare

Alector Inc

NASDAQ: ALEC Biotechnology
$2.57
▲ $0.01 (+0.39%) today
Markets closed · 10:38pm ET

24/7 Wall St. View

ALEC at a Glance

Valuation
Market cap
$381.1M
P/E ratio
6.9
Profitability
Revenue (TTM)
$173.5M
Profit margin
23.9%
EPS (TTM)
$0.37
Price
52-week range
$1 – $3
Street target
$4.42
Earnings
Q3 2026 EPS
$1.11
vs. $0.06 est.
+1,690.3%

Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ALEC alector.com

About Alector

Alector is a preclinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Lewy body dementia. Its programs aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Every program in its current pipeline is built on the proprietary Alector Brain Carrier (ABC), a blood-brain barrier platform that binds a distinct region of the transferrin receptor. ABC is designed to increase brain delivery of antibodies, enzymes, proteins and siRNA through peripheral (subcutaneous) dosing.

The lead program is AL137, an ABC-enabled anti-pyroglutamate-3 amyloid beta antibody for Alzheimer's disease designed for monthly subcutaneous administration. It is targeting first-in-human dosing in Australia no later than April 2027. Siliconcandidates in the siRNA portfolio include:
- AL164 (tau), for Alzheimer's disease and other tauopathies
- AL062 (alpha-synuclein), for Parkinson's disease and Lewy body dementia
- ADP065 (NLRP3), an earlier-stage program

AL164 and AL062 are targeting first-in-human studies in Q2 2028.

Alector earns collaboration and licensing revenue. It exclusively licensed its AL050 GCase enzyme replacement therapy to Genentech in exchange for a $100 million upfront payment, up to $1.17 billion in milestones and royalties. Its former GSK collaboration was terminated in July 2026. The company has wound down its earlier clinical programs, latozinemab and nivisnebart. Updated

ALEC Coverage

Frequently Asked Questions

What does Alector do?

Alector is a preclinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Lewy body dementia. Its programs aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function.

What is the ALEC stock price target?

The Wall Street consensus 12-month price target for ALEC is $4.42.